Rituximab as First-Line Maintenance Therapy Following Rituximab-Containing Therapy for Follicular LymphomaProfile Report

被引：0
|
作者：
Jamie D. Croxtall
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
BioDrugs | 2011年 / 25卷
关键词：
Maintenance Therapy; Induction Therapy; Follicular Lymphoma; Observation Group; Progressive Multifocal Leukoencephalopathy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：329 / 331
页数：2
相关论文
共 50 条
  • [21] Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability
    Zephir, H.
    Bernard-Valnet, R.
    Lebrun-Frenay, C.
    Outteryck, O.
    Audoin, B.
    Bourre, B.
    Pittion, S.
    Wiertlewski, S.
    Ouallet, J. -C.
    Ciron, J.
    Neau, J. -P.
    Clavelou, P.
    Marignier, R.
    Brassat, D.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 243 - 244
  • [22] Is rituximab suitable for use as a first-line biologic therapy for RA?
    Kleiner, Anatole
    Looney, R. John
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2008, 4 (11): : 574 - 575
  • [23] Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?
    Cravedi, Paolo
    Remuzzi, Giuseppe
    Ruggenenti, Piero
    NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 261 - 269
  • [24] Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability
    Zephir, Helene
    Bernard-Valnet, Raphael
    Lebrun, Christine
    Outteryck, Olivier
    Audoin, Bertrand
    Bourre, Bertrand
    Pittion, Sophie
    Wiertlewski, Sandrine
    Ouallet, Jean Christophe
    Neau, Jean-Philippe
    Ciron, Jonathan
    Clavelou, Pierre
    Marignier, Romain
    Brassat, David
    JOURNAL OF NEUROLOGY, 2015, 262 (10) : 2329 - 2335
  • [25] Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability
    Hélène Zéphir
    Raphaël Bernard-Valnet
    Christine Lebrun
    Olivier Outteryck
    Bertrand Audoin
    Bertrand Bourre
    Sophie Pittion
    Sandrine Wiertlewski
    Jean Christophe Ouallet
    Jean-Philippe Neau
    Jonathan Ciron
    Pierre Clavelou
    Romain Marignier
    David Brassat
    Journal of Neurology, 2015, 262 : 2329 - 2335
  • [26] Use of Rituximab as First-Line Therapy in Pediatric Multiple Sclerosis
    Willis, E.
    Lewis, H. E.
    Haire, J.
    Kiss, A.
    ANNALS OF NEUROLOGY, 2025, 96 : S134 - S135
  • [27] Is rituximab suitable for use as a first-line biologic therapy for RA?
    Anatole Kleiner
    R John Looney
    Nature Clinical Practice Rheumatology, 2008, 4 : 574 - 575
  • [28] Successful Rituximab First-line Induction Therapy for Granulomatosis with Polyangiitis
    Goerl, N.
    Kneitz, C.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 145 - 145
  • [29] Efficacy of rituximab-containing regimens used as first-line and rescue therapy for giant cell hepatitis with autoimmune hemolytic anemia a retrospective study
    Zhang, Xue-Yuan
    Gong, Jing-Yu
    Wang, Jian-She
    Feng, Jia-Yan
    Chen, Lian
    Xie, Xin-Bao
    Lu, Yi
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [30] Cost-Effectiveness Analysis of Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma Responding to Induction Therapy at the First Line
    Castro Gomez, Antonio J.
    Lopez-Guillermo, Armando
    Rueda Dominguez, Antonio
    Salar, Antonio
    Varela Moreno, Cristina
    Rubio-Terres, Carlos
    REVISTA ESPANOLA DE SALUD PUBLICA, 2012, 86 (02): : 163 - 176
12345